Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2021 Feb 18;54(5):1006–1007. doi: 10.1016/j.jmii.2021.01.013

Eosinopenia in COVID-19: What we missed so far?

Benjamin Davido 1,, Bethsabee Partouche 2, Karim Jaffal 3, Pierre de Truchis 3, Marie Herr 4,5, Marion Pepin 6,7
PMCID: PMC7891077  PMID: 33648873

Dear Editor,

We have read with great interest the article published by Outh et al. concerning the use of peripheral eosinopenia to predict the medical causes of admission in a medicine ward during the first wave of COVID-19 (n = 121).1

The title of the article can be misleading while it states that eosinophil count (EC) below 100/mm3 is highly evocative of COVID-19, meanwhile conclusion supports that a threshold below 10/mm3 is more relevant. In the present study the control group is heterogeneous, with patients suffering from respiratory tract infections with a negative SARS-CoV-2 PCR (n = 14), patients with other viruses or bacterial infections (n = 20), and patients with other non-infectious diagnoses (n = 30). Therefore, at baseline the CRP level already differs significantly between the 2 groups (Table 2), with a median CRP value of 69.8 mg/L in the COVID-19 group versus 14.7 mg/L in the non-COVID-group (p = 0.001). In the same way, Li et al. already described that eosinopenia (<20/mm3) was associated with COVID-19 in China,2 but authors highlighted that EC had to be interpreted in the light of the CRP level, considering their control group had a normal CRP value (<4 mg/L).

To better approach the use of eosinopenia, it must be reminded that there is no consensual threshold and that normal value for EC is ranging from 1 to 3% of total leukocytes.3 Historically, eosinopenia has been firstly described in 1893 by Zappert et al. in response of a systemic inflammation. Moreover it has to be taken into account that eosinopenia has not been established to distinguish viral from bacterial infection in adults. Indeed, our first work focusing on bacterial infections reported eosinopenia (EC < 100/mm3) supporting the fact that eosinopenia is not specific of COVID-19. In addition our study showed that the normalization of the EC was related to the control of the bacterial infection.4

To our knowledge, it has been only once suggested, in a pediatric setting, that eosinopenia could help to distinguish bacterial from viral infection and was associated with bacterial meningitis.5 Indeed, eosinopenia is not specific neither of bacterial nor viral infection, but related to the severity of the infection. For this purpose, critical care physicians monitor EC in common daily practice to predict the severity of sepsis in bacterial infections for decades.6 For instance, undetectable EC (0/mm3) at admission has been shown to be predictive of Clostridium difficile infection's severity and mortality in a large study with 2065 patients.7

Although, EC seems to be very interesting and cost-effective, we believe that the design and the nature of the study by Outh et al.1 cannot support the use of eosinopenia for the diagnosis of COVID-19 without considering confounding factors in a multivariate analysis. Nevertheless, EC might help to predict the severity of the SARS-CoV-2 infection and the requirement of intensive care unit transfer and should be evaluate in further studies.

Funding

No funding obtained.

Declaration of competing interest

The authors report no conflicts of interest.

Footnotes

I confirm that all listed authors have contributed to this work and approved the paper.

References

  • 1.Outh R., Boutin C., Gueudet P., Suzuki M., Saada M., Aumaître H. Eosinopenia <100/μL as a marker of active COVID-19: an observational prospective study. J Microbiol Immunol Infect. 2021 doi: 10.1016/j.jmii.2020.12.005. http://www.ncbi.nlm.nih.gov/pubmed/33468435 Available at: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Li Q., Ding X., Xia G., Chen H., Chen F., Geng Z. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study. EClinicalMedicine. 2020;23:100375. doi: 10.1016/j.eclinm.2020.100375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Rothenberg M.E. Eosinophilia. N Engl J Med. 1998;338:1592–1600. doi: 10.1056/NEJM199805283382206. [DOI] [PubMed] [Google Scholar]
  • 4.Davido B., Makhloufi S., Matt M., Calin R., Senard O., Perronne C. Changes in eosinophil count during bacterial infection: revisiting an old marker to assess the efficacy of antimicrobial therapy. Int J Infect Dis. 2017;61:62–66. doi: 10.1016/j.ijid.2017.06.005. http://linkinghub.elsevier.com/retrieve/pii/S1201971217301595 Available at: [DOI] [PubMed] [Google Scholar]
  • 5.Debray A., Nathanson S., Moulin F., Salomon J., Davido B. Eosinopenia as a marker of diagnosis and prognostic to distinguish bacterial from aseptic meningitis in pediatrics. Eur J Clin Microbiol Infect Dis. 2019;38 doi: 10.1007/s10096-019-03614-y. [DOI] [PubMed] [Google Scholar]
  • 6.Abidi K., Belayachi J., Derras Y., Khayari M.E., Dendane T., Madani N. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Crit Care. 2008;12:R59. doi: 10.1186/cc6883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kulaylat A.S., Buonomo E.L., Scully K.W., Hollenbeak C.S., Cook H., Petri W.A., Jr Development and validation of a prediction model for mortality and adverse outcomes among patients with peripheral eosinopenia on admission for Clostridium difficile infection. JAMA Surg. 2018;153(12):1127–1133. doi: 10.1001/jamasurg.2018.3174. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Microbiology, Immunology, and Infection are provided here courtesy of Elsevier

RESOURCES